LAVAL, QC and ATHENS, Greece, Dec. 1, 2011 /CNW Telbec/ - BELLUS Health
Inc. (TSX: BLU) ("BELLUS Health") announced today that it has signed an
exclusive license and distribution agreement (the "Agreement") with
Integris Pharma Ltd., a wholly owned subsidiary of Coronis Research
S.A., a leading independent Clinical Research Organization in Greece.
Pursuant to the Agreement, Integris has secured the exclusive right to
market and sell VIVIMIND™ in Greece and Cyprus. VIVIMIND™ is a patented
natural health product that has been shown to help support the specific
area of the brain known as the hippocampus, the region responsible for
memory and learning. Financial terms of this agreement were not
Integris Pharma Ltd. intends to immediately proceed with filing for
regulatory approval and expects to launch VIVIMIND™ in Greece and
Cyprus in the second quarter of 2012.
"Integris puts the utmost importance on products that meet the highest
levels quality, safety and efficacy and VIVIMIND™ fits perfectly within
those criteria" said Dr. Harry Therianos MD, PhD, Managing Director of
Integris Pharma Ltd. "Given the strong clinical data generated from two
phase III clinical trials conducted in over 2,000 patients and
considering the completeness of the VIVIMIND™ regulatory dossier which
includes approvals in Canada, Italy and Spain, we expect to receive
formal regulatory approval from the Greek authorities in the first
quarter of 2012. We look forward to making this innovative product for
cognition available to consumers throughout Greece and Cyprus."
concluded Dr. Therianos.
"This transaction fits within our strategy of forming partnerships with
strong regional industry players to build a worldwide distribution
network for VIVIMIND™. With its in-depth understanding of this region,
Integris Pharma is the right partner to realize VIVIMIND's™ commercial
potential in Greece and Cyprus" said Mr. Roberto Bellini, President and
Chief Executive Officer of BELLUS Health.
VIVIMIND™ is scientifically proven to help support the specific area of
the brain known as the hippocampus, a region responsible for memory and
learning. The active ingredient behind VIVIMIND™, homotaurine, is a
naturally occurring amino acid with unique properties found in certain
seaweeds. VIVIMIND™ is intended to be used by normal aging adults.
VIVIMIND™ was subject to more than 15 years of significant scientific
research, including clinical testing in over 2,000 people at European,
American and Canadian medical centres. In a large, controlled clinical
study, VIVIMIND™ was shown to reduce by 68% the hippocampus volume loss
in Alzheimer's disease patients over 18 months.1
Regulatory approvals for the commercial sale of VIVIMIND™ were obtained
in Italy and in Spain in 2009, and a Natural Health Product Number was
issued by Health Canada for VIVIMIND™ in September 2010.
1 Gauthier S. et al, Journal Nutrition Health Aging, 2009; 13 (6): 550-7
About Integris Pharma Ltd.
Integris Pharma Ltd. is a specialty pharmaceutical company operating
exclusively in the CNS area. Integris representatives detail more than
1,000 psychiatrists & neurologists, all over Greece.
About CORONIS Research SA
CORONIS Research SA is a leading Clinical Research Organization (CRO)
with broad expertise in every phase of the drug development and
clinical research continuum, delivering a full spectrum of services to
national and international pharmaceutical, biotechnology and medical
device industries and other healthcare-related organisations.
About BELLUS Health
BELLUS Health is a development-focused health company concentrating on
the development of products that provide innovative health solutions
and address critical unmet medical needs. For further information on
BELLUS Health, please visit www.bellushealth.com .
Forward Looking Statements
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may
constitute forward-looking statements. Such statements, based as they
are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown, many of which are
beyond BELLUS Health Inc.'s control. Such risks include but are not
limited to: the ability to obtain financing immediately in current
markets, the impact of general economic conditions, general conditions
in the pharmaceutical and/or nutraceutical industry, changes in the
regulatory environment in the jurisdictions in which the BELLUS Health
Group does business, stock market volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation,
achievement of forecasted burn rate, and that actual results may vary
once the final and quality-controlled verification of data and analyses
has been completed. Consequently, actual future results may differ
materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue
reliance, if any, on any forward-looking statements included in this
news release. These statements speak only as of the date made and
BELLUS Health Inc. is under no obligation and disavows any intention to
update or revise such statements as a result of any event,
circumstances or otherwise, unless required by applicable legislation
or regulation. Please see the Company's public fillings including the
Annual Information Form of BELLUS Health Inc. for further risk factors
that might affect the BELLUS Health Group and its business
SOURCE BELLUS HEALTH INC.
For further information:
NATIONAL Public Relations